Rapid Micro Biosystems Inc (RPID) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Rapid Micro Biosystems Inc stock (RPID) is currently trading at $2.40. Rapid Micro Biosystems Inc PS ratio (Price-to-Sales) is 3.11. Analyst consensus price target for RPID is $8.00. WallStSmart rates RPID as Sell.
- RPID PE ratio analysis and historical PE chart
- RPID PS ratio (Price-to-Sales) history and trend
- RPID intrinsic value — DCF, Graham Number, EPV models
- RPID stock price prediction 2025 2026 2027 2028 2029 2030
- RPID fair value vs current price
- RPID insider transactions and insider buying
- Is RPID undervalued or overvalued?
- Rapid Micro Biosystems Inc financial analysis — revenue, earnings, cash flow
- RPID Piotroski F-Score and Altman Z-Score
- RPID analyst price target and Smart Rating
Rapid Micro Biosystems Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Rapid Micro Biosystems Inc (RPID) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Rapid Micro Biosystems Inc (RPID) Key Strengths (2)
Revenue surging 37.30% year-over-year
57.70% held by institutions, strong professional interest
Supporting Valuation Data
Rapid Micro Biosystems Inc (RPID) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.1x book value
Revenue is fairly priced at 3.11x sales
Rapid Micro Biosystems Inc (RPID) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 37.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (3.11), Price/Book (3.15) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -86.80%, Operating Margin at -108.20%, Profit Margin at -140.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -86.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 37.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RPID Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RPID's Price-to-Sales ratio of 3.11x trades 36% below its historical average of 4.86x (0th percentile). The current valuation is 51% below its historical high of 6.33x set in Mar 2026, and 0% above its historical low of 3.11x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~6.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Rapid Micro Biosystems Inc (RPID) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Rapid Micro Biosystems Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 34M with 37% growth year-over-year. The company is currently unprofitable, posting a -140.3% profit margin.
Key Findings
Revenue growing at 37% YoY, reaching 34M. This pace significantly outperforms most MEDICAL DEVICES peers.
The company is unprofitable with a -140.3% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Rapid Micro Biosystems Inc maintain 37%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Rapid Micro Biosystems Inc.
Bottom Line
Rapid Micro Biosystems Inc is a high-conviction growth story with revenue accelerating at 37% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -140.3% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(25 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SPIGNESI, ROBERT G. JR. Director, PRESIDENT AND CEO | Sell | -17,922 |
| Insider | Type | Shares |
|---|---|---|
SPIGNESI, ROBERT G. JR. Director, PRESIDENT AND CEO | Sell | -38,327 |
| Insider | Type | Shares |
|---|---|---|
LONGITUDE, CAPITAL PARTNERS II, LLC 10% Owner | Sell | -49,000 |
| Insider | Type | Shares |
|---|---|---|
LONGITUDE, CAPITAL PARTNERS II, LLC 10% Owner | Sell | -27,500 |
| Insider | Type | Shares |
|---|---|---|
LONGITUDE, CAPITAL PARTNERS II, LLC 10% Owner | Sell | -27,500 |
| Insider | Type | Shares |
|---|---|---|
LONGITUDE, CAPITAL PARTNERS II, LLC 10% Owner | Sell | -46,000 |
Data sourced from SEC Form 4 filings
Last updated: 12:58:56 PM
About Rapid Micro Biosystems Inc(RPID)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Rapid Micro Biosystems Inc is an innovative biotechnology company focused on revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated growth-based microbial detection technologies, the firm significantly improves the precision and efficiency of microbial testing, ensuring high product quality and regulatory compliance. With an increasing demand for rapid, reliable quality control solutions in regulated environments, Rapid Micro is well-positioned to meet these urgent market needs and lead the evolution of microbiological testing methodologies.